Arthrosi Therapeutics

Arthrosi Therapeutics is a private, clinical-stage biotech company advancing its lead candidate, AR882 (pozdeutinurad), a next-generation urate transporter 1 (URAT1) inhibitor, through pivotal Phase 3 trials for gout and tophaceous gout. The company has demonstrated strong execution, completing Phase 3 enrollment ahead of schedule and securing a substantial $153 million Series E financing in late 2025. In a major strategic development, Arthrosi has entered into an agreement to be acquired by Swedish Orphan Biovitrum (Sobi), which will provide the resources and global reach to potentially bring AR882 to market.

Discovery and development of selective small molecule URAT1 inhibitors for urate lowering, designed for superior safety and efficacy in patients with renal impairment.

AR882 competes in the urate-lowering drug market against xanthine oxidase inhibitors (allopurinol, febuxostat) and first-generation URAT1 inhibitors (lesinurad). Its key differentiation is a purported best-in-class efficacy and safety profile, specifically in patients with chronic kidney disease, a segment poorly served by current therapies.